ANDREW YEE to Aged, 80 and over
This is a "connection" page, showing publications ANDREW YEE has written about Aged, 80 and over.
Connection Strength
0.248
-
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. Blood Adv. 2025 Mar 11; 9(5):1163-1170.
Score: 0.102
-
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study. Nat Commun. 2026 Apr 08; 17(1).
Score: 0.027
-
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenstr?m macroglobulinemia. Blood Adv. 2025 Sep 23; 9(18):4568-4579.
Score: 0.026
-
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma. Blood Cancer J. 2024 12 23; 14(1):224.
Score: 0.025
-
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. Leuk Lymphoma. 2024 12; 65(12):1789-1800.
Score: 0.025
-
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018 03; 180(6):831-839.
Score: 0.015
-
Exercises for mechanical neck disorders: A Cochrane review update. Man Ther. 2016 Aug; 24:25-45.
Score: 0.014
-
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016 09; 57(9):2071-6.
Score: 0.013